AstraZeneca's Asthma Candidate Shows Promising Results

AstraZeneca Plc. announced a subgroup analysis from SIROCCO and CALIMA phase III studies. The studies revealed the efficacy of benralizumab and also showed that this antibody provides increased benefits to patients.